S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

Key facts

Sponsor

SWOG Cancer Research Network

Principal Investigator

Jeffrey E. Lancet, MD

H. Lee Moffitt Cancer Center and Research Institute

Intervention

arsenic trioxide(drug)

Enrollment

78 enrolled

Eligibility

18-120 years · All sexes

Timeline

2007 – 2018

Study locations (30)

• Sutter Cancer Center at Roseville Medical Center, Roseville, California, United States
• Sutter Cancer Center, Sacramento, California, United States
• Stanford Cancer Center, Stanford, California, United States
• Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States
• Tunnell Cancer Center at Beebe Medical Center, Lewes, Delaware, United States
• CCOP - Christiana Care Health Services, Newark, Delaware, United States
• M.D. Anderson Cancer Center at Orlando, Orlando, Florida, United States
• H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States
• Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center, Boise, Idaho, United States
• Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
• Hematology and Oncology Associates, Chicago, Illinois, United States
• University of Chicago Cancer Research Center, Chicago, Illinois, United States
• Kellogg Cancer Care Center, Highland Park, Illinois, United States
• Provena St. Mary's Regional Cancer Center - Kankakee, Kankakee, Illinois, United States
• North Shore Oncology and Hematology Associates, Limited - Libertyville, Libertyville, Illinois, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Acute promyelocytic leukemia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07563179
  Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
  Shenzhen University General Hospital
• RECRUITINGPHASE3NCT07504458
  Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
  Quetzal Therapeutics
• RECRUITINGPHASE3NCT07223814
  Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
  Stichting Hemato-Oncologie voor Volwassenen Nederland
• ACTIVE NOT RECRUITINGNANCT07187505
  Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia
  Anhui Medical University
• RECRUITINGPHASE3NCT07503730
  Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL).
  First Affiliated Hospital Xi'an Jiaotong University
• ENROLLING BY INVITATIONNANCT06697327
  Daunorubicin + Cytarabine + Venetoclax in de Novo AML
  Anhui Medical University
• RECRUITINGPHASE1NCT06313437
  Revumenib in Combination With 7+3 + Midostaurin in AML
  Richard Stone, MD
• RECRUITINGPHASE3NCT06578247
  Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
  Daiichi Sankyo

See all trials for Acute promyelocytic leukemia →